ESC 365 - Thromboembolic prevention after TAVI: antiplatelets or anticoagulants? Positioning of the topic

ESC Premium Access

Thromboembolic prevention after TAVI: antiplatelets or anticoagulants? Positioning of the topic

Session: Thromboembolic prevention after TAVI: antiplatelets or anticoagulants?

Topic: Non coronary cardiac interventions

Speaker: Professor R. Mehran (New York, US)

Event: ESC Congress 2016

Congress Presentation

Add to my library

About the speaker

Professor Roxana Mehran

Icahn School of Medicine at Mount Sinai, New York (United States of America)

53 presentations

12 followers

4 more presentations in this session

All we need are antiplatelet agents – PRO

Speaker: Doctor A. Colombo (Milan, IT)

All we need are antiplatelet agents – CON

Speaker: Professor L. Sondergaard (Copenhagen, DK)

All we need are antiplatelet agents – Discussion PRO/CONTRA.

Thromboembolic prevention after TAVI: antiplatelets or anticoagulants? - Conclusion

Speaker: Professor S. Windecker (Bern, CH)

Access the full session

Thromboembolic prevention after TAVI: antiplatelets or anticoagulants?

Speakers: Professor R. Mehran, Doctor A. Colombo, Professor L. Sondergaard, Professor S. Windecker

About the event

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources